Zhanling International Ltd 3Q 2026: Revenue $0 Net income $(6,597), EPS $(0.00) — 10-Q Summary

Zhanling International Ltd reported 3Q 2026 results with $0 revenue and a net loss of $6,597, improved from a $8,126 loss in the prior-year quarter. Diluted EPS was $(0.00), unchanged year-over-year. The company remains in development stage, focusing on acquisitions and cost management.

Original reporting
Published Oct 13, 2026, 10:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Zhanling International Ltd 3Q 2026: Revenue $0 Net income $(6,597), EPS $(0.00) — 10-Q Summary — source image
Decision brief

The 30-second read

Low
01

Why it matters

The filing confirms the firm remains pre‑revenue and is seeking a merger or acquisition to start operations, indicating continued cash burn and financing risk.

02

Market read

The report is a routine earnings disclosure for a small, non‑US listed company with limited trading relevance.

03

What to watch

Potential hidden value in the company's pipeline of acquisition targets and upcoming equity financing.

Relevance 6/10Novelty 6/10Timing: same-day filing

Background

Zhanling International Ltd filed its 10‑Q for Q3 2026, reporting zero revenue and a reduced net loss.

Market effects

Minimal impact; the company is a micro‑cap development stage firm with no revenue.

Limited to niche Chinese consumption sector investors.

Negligible for broader markets.

Counterpoint

If the merger/acquisition materializes, the stock could experience a breakout despite current losses.

Key entities

  • Zhanling International Ltd

    Development‑stage firm targeting a merger in China's consumption sector.

Related articles

$DPZMed

Domino's Pizza, Inc. Q3 2026 Earnings Call Summary

Domino's Pizza, Inc. reported Q3 2026 earnings, highlighting strong order growth but tempered U.S. same-store sales due to macroeconomic pressures. Management expects low-single-digit U.S. same-store sales growth for 2026 and lowered net store growth guidance to 125-150 units. International performance remains weak, with flat same-store sales projected for the year. The company is focusing on operational consistency, targeted promotions, and franchisee profitability to drive growth.

$JNJMed

Johnson & Johnson Q3 2026 Earnings Call Summary

Johnson & Johnson reported Q3 2026 operational sales growth of 6%, driven by 17% oncology growth and 68% Tremfya growth, offsetting MedTech's 2.5% growth. Management raised 2026 guidance to 6.7%-7.1% and expects to exceed $100B in annual revenue. The DePuy Synthes separation is on track for mid-2027. MedTech underperformance was attributed to competitive pressures and geopolitical instability.

$UNHMedAI 8/10

UnitedHealth Group stock trims gains on profit outlook increase

UnitedHealth Group (UNH) raised its full-year profit forecast to at least $20.50 per share, up from $19.50-$20, after Q3 earnings beat estimates. The stock initially jumped 5% but trimmed gains. The company is executing a turnaround plan. Year-to-date, the stock is up 14%. Berkshire Hathaway previously sold its stake in UNH.

$GSMedAI 9/10

[The Goldman Sachs Group Q3 2026 Earnings Call] Goldman Posts Second-Best Quarter Ever With $18.7B Revenue, 72% Equities Surge as Asia Bet Pays Off

Goldman Sachs reported Q3 2026 net revenues of $18.7B, its second-highest ever, driven by a 72% surge in equities revenues and record investment banking advisory fees. CEO David Solomon highlighted strong performance with EPS of $17.01, ROE of 18.7%, and ROTE of 20.5%. Asia's share of firm-wide revenues increased, reflecting strategic investments. Investment banking advisory revenues hit a quarterly record of $1.7B, while Asset & Wealth Management revenues rose 14% to $5.1B.